Policy Blog – August 13, 2026 – Industry Welcomes New PDUFA VIII Agreement
The FDA and biopharmaceutical industry have reached an important agreement on the next iteration of the Prescription Drug User Fee Act (PDUFA), setting the stage for congressional reauthorization of a program that has been central to the FDA’s drug review process for more than three decades. The FDA recently released its proposed PDUFA VIII commitment letter, outlining […]